An investigation on behalf of investors in ADMA Biologics, Inc. (NASDAQ: ADMA) shares over potential wrongdoing at ADMA Biologics, Inc. was announced.
San Diego, CA -- (SBWIRE) -- 06/20/2019 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at ADMA Biologics, Inc.
Investors who purchased shares of ADMA Biologics, Inc. (NASDAQ: ADMA) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain ADMA Biologics directors breached their fiduciary duties and caused damage to the company and its shareholders.
ADMA Biologics, Inc. reported that its annual Total Revenue rose from $15.76 million in 2017 to $16.98 million in 2018 and that its Net Loss increased from $43.75 million in 2017 to $65.74 million in 2018.
Shares of ADMA Biologics, Inc. (NASDAQ: ADMA) declined from $6.93 per share in September 2018 to $3.63 per share on June 19, 2019.
Those who purchased shares of ADMA Biologics, Inc. (NASDAQ: ADMA), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels